- Home
- TNXP vs PVLA Comparison
TNXP vs PVLA Comparison
Compare TNXP & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- PVLA
- Stock Information
- Founded
- TNXP 2007
- PVLA 2015
- Country
- TNXP United States
- PVLA United States
- Employees
- TNXP N/A
- PVLA N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- TNXP Health Care
- PVLA Health Care
- Exchange
- TNXP Nasdaq
- PVLA Nasdaq
- Market Cap
- TNXP 335.6M
- PVLA 285.2M
- IPO Year
- TNXP N/A
- PVLA N/A
- Fundamental
- Price
- TNXP $51.35
- PVLA $47.30
- Analyst Decision
- TNXP Buy
- PVLA Strong Buy
- Analyst Count
- TNXP 1
- PVLA 11
- Target Price
- TNXP $70.00
- PVLA $55.36
- AVG Volume (30 Days)
- TNXP 1.8M
- PVLA 181.6K
- Earning Date
- TNXP 08-11-2025
- PVLA 08-14-2025
- Dividend Yield
- TNXP N/A
- PVLA N/A
- EPS Growth
- TNXP N/A
- PVLA N/A
- EPS
- TNXP N/A
- PVLA N/A
- Revenue
- TNXP $9,831,000.00
- PVLA N/A
- Revenue This Year
- TNXP $22.87
- PVLA N/A
- Revenue Next Year
- TNXP $711.66
- PVLA N/A
- P/E Ratio
- TNXP N/A
- PVLA N/A
- Revenue Growth
- TNXP N/A
- PVLA N/A
- 52 Week Low
- TNXP $6.76
- PVLA $11.17
- 52 Week High
- TNXP $130.00
- PVLA $47.97
- Technical
- Relative Strength Index (RSI)
- TNXP 55.76
- PVLA N/A
- Support Level
- TNXP $42.12
- PVLA N/A
- Resistance Level
- TNXP $69.97
- PVLA N/A
- Average True Range (ATR)
- TNXP 6.06
- PVLA 0.00
- MACD
- TNXP 1.01
- PVLA 0.00
- Stochastic Oscillator
- TNXP 45.73
- PVLA 0.00
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.